Perspectives on breast cancer management: Tailoring treatment to the individual patient

Breast Care

Volumn 3, Issue SUPPL. 1, 2008, Pages 21-23

  Thomssen, Christoph ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYTOCHROME P450 2D6; DRUG METABOLITE; ENDOXIFEN; EVEROLIMUS; LAPATINIB; PACLITAXEL; PAZOPANIB; PLASMINOGEN ACTIVATOR INHIBITOR; TAMOXIFEN; TRASTUZUMAB; UROKINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RECEPTOR BINDING; HUMAN; MONOTHERAPY; PHARMACOGENETICS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 44649113205     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000119749     Document Type: Conference Paper

References (18)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998;352:930-942.
2. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-1467.
3. Goldhirsch A, Wood WC, Gelber RD, et al.: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-1144.
4. Eifel P, Axelsson JA, Costa J, et al.: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer November 1-3 2000. J Natl Cancer Inst 2001;93:979-989.
5. Wang Y, Klijn JG, Zhang Y, et al.: Gene-expression profiles to predict distant metastasis of lymphnode-negative primary breast cancer. Lancet 2005;671-679.
6. Van't Veer LJ, Dai H, van de Vijver MJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
7. Van de Vijver MJ, He YD, van't Veer EJ, et al.: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
8. Ein-Dor L, Kela I, Getz G, et al.: Outcome signature genes in breast cancer. Is there a unique set? Bioinformatics 2005;21:171-178.
9. Piccart MJ, Loi S, van't Veer L, et al.: Multi-center external validation study of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: are the results still outperforming clinical-pathological criteria? Breast Cancer Res Treat 2004;88(suppl 1):abstr 38.
10. Vetter M, Kantelhardt EJ, Annecke K, et al.: Invasionsfaktoren uPA/PAI-1 im Tumorgewebe bei Patientinnen mit primärem Mammakarzinom: Von Forschungsergebnissen zur klinischen Anwendung am Beispiel der NNBC 3-Europe Studie. Geburtsh-Frauenheilk 2007;67:1144-1152.
11. Jänicke F, Schmitt M, Ulm K, et al.: Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 1989;2:1049.
12. Duffy MJ, Reilly D, O'Sullivan, et al.: Urokinase-plaminogen activator: a new and independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-6829.
13. Harris L, Fritsche H, Mennel R, et al.: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5268-5312.
14. Stearns V, Johnson MD, Rae JM, et al.: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-1764.
15. Goetz MP, Rae JM, Suman VJ, et al.: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcome of efficacy and hot flashes. J Clin Oncol 2005;23:9312-9318.
16. Mortimer J, Flatt S, Parker B, et al.: Tamoxifen, hot flashes and recurrence in breast cancer: support for pharmacogenetics. Proc Am Soc Clin Oncol 2007;25(18S):abstr 500.
17. Linderholm B, Tavelin B, Grankvist K, et al.: Does vascular enothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer? Br J Cancer 1999;81:727-733.
18. Miller KD, Wang M, Gralow J, et al.: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy of locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). SABCS, San Antonio, TX, 2005, abstr 3.